Ainos earnings release, August 3, 2026

Ainos, Inc. (AIMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Ainos

Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics

Markets

Ainos,

Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”) today announced results for the second quarter ended

June 30, 2026, and provided a business update on continued execution progress for AI Nose across semiconductor manufacturing, industrial infrastructure, robotics, and healthcare-related environments.

Eddy

Tsai, Chairman, President and Chief Executive Officer, commented:

“We believe AI is increasingly expanding beyond understanding text, images, and speech toward interpreting real-world environmental information.

This vision continues to guide Ainos’ commercialization strategy for AI Nose. We believe future semiconductor manufacturing, industrial infrastructure, healthcare environments, and robotics applications will increasingly require intelligent environmental awareness, and

AI Nose continues to advance steadily toward that objective.”

“During the first half of 2026, we continued executing our commercialization roadmap by expanding AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and robotics environments. I believe these deployments not only support commercial applications, but also continuously expand our real-world environmental dataset, strengthen our Smell ID dataset, and enhance the learning and environmental pattern recognition capabilities of our Smell Language Model (SLM), enabling our Smell AI Platform to continue evolving.”

“Since

December 2025, AI Nose has accumulated approximately 613 million industrial smell data records, primarily from semiconductor manufacturing environments. We believe these growing real-world datasets represent an important foundation for the long-term development of Smell AI.

We believe every new deployment expands application opportunities while further strengthening our platform’s ability to recognize and understand diverse environmental patterns, allowing our Smell AI Platform to continuously learn and evolve through real-world experience.”

“We are encouraged by the progress of our commercialization activities. As existing deployments continue to advance, strategic collaborations expand, and additional real-world data strengthens the platform, we remain focused on executing our commercialization strategy, expanding real-world applications, and steadily advancing the long-term development of our Smell AI Platform.”

Christopher

Lee, Chief Financial Officer of Ainos, added, “Our second-quarter results reflect Ainos’ continued execution of its commercialization strategy. We are focused on supporting AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and other real-world environments while advancing commercialization initiatives and expanding strategic collaborations that strengthen the Company’s long-term foundation. We continue to believe our activities will help support broader revenue generation opportunities in the second half of 2026.”

Mr.

Lee continued, “We remain committed to disciplined capital allocation and financial management while supporting our core commercialization strategy, technology development, and deployment priorities. We will continue focusing on operational efficiency, strategic deployment activities, and financial discipline as we execute our long-term commercialization strategy.”

Second

Quarter 2026 and Recent Operational Highlights

Ainos is focused on execution, deployment, Smell ID dataset expansion, smell language model development, and strategic commercial expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.

About

AI Nose

AI

Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision

MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language

Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.

Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.

About

Ainos, Inc.

Ainos,

Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of “AI” and “Nose,” is redefining machine perception for the sensory age.

To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter,

(

@AinosInc) and

LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three months ended June 30, — (Unaudited)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Revenues1524,663313110,870
Cost of revenues-53-937-816-19,170
Gross profit (loss)993,726-50391,700
Operating expenses:Research and development (including amounts of related party of $220,619 and $449,570 for the three and six months ended June 30, 2026, and $235,424 and $481,685 for the three and six months ended June 30, 2025, respectively)1,850,4091,911,8003,540,2693,635,884
Operating expenses:Selling, general and administrative2,548,7761,837,6133,141,9613,364,374
Operating expenses:Total operating expenses4,399,1853,749,4136,682,2307,000,258
Operating expenses:Loss from operations-4,399,086-3,745,687-6,682,733-6,908,558
Non-operating (expenses) income, net:Interest expense-200,162-177,957-377,038-358,402
Non-operating (expenses) income, net:Other income, net4,517-161,3465,240-104,052
Non-operating (expenses) income, net:Total non-operating expenses, net-195,645-339,303-371,798-462,454
Non-operating (expenses) income, net:Net loss before income taxes-4,594,731-4,084,990-7,054,531-7,371,012
Non-operating (expenses) income, net:Net loss-4,594,731-4,084,990-7,054,531-7,371,012
Non-operating (expenses) income, net:Net loss per common share - basic and diluted-0.62-0.99-1.05-2.02
Non-operating (expenses) income, net:Weighted-average shares used in computing net loss per common share-basic and diluted7,357,1504,122,1316,698,0303,649,994

Balance Sheet

December 31, — Condensed Consolidated Balance Sheets

June 30, – 2026 – (Unaudited)December 31, – 2025
Current assets:Cash and cash equivalents1,422,912417,353
Current assets:Accounts receivable22
Current assets:Inventory, net308,743295,565
Current assets:Other current assets456,883425,859
Current assets:Total current assets2,188,5381,138,799
Current assets:Intangible assets, net16,983,32919,226,003
Current assets:Property and equipment, net239,635343,281
Current assets:Other assets149,983163,025
Current assets:Total assets19,561,48520,871,108
Current liabilities:Contract liabilities350,000350,000
Current liabilities:Convertible notes payable11,000,000
Current liabilities:Loan payable2,812,940
Current liabilities:Accrued expenses and other current liabilities2,114,560728,683
Current liabilities:Total current liabilities16,277,5001,078,683
Current liabilities:Convertible notes payable - noncurrent11,000,000
Current liabilities:Other long-term liabilities1,229,843
Current liabilities:Total liabilities16,277,50013,308,526
Stockholders’ equity:Common stock, $0.01 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025, 8,544,073 and 6,982,675 shares issued and 7,384,073 and 5,822,675 shares outstanding as of June 30, 2026, and December 31, 2025, respectively85,44169,827
Stockholders’ equity:Treasury stock, at cost (1,160,000 shares held as of June 30, 2026 and December 31, 2025)-1,972,000-1,972,000
Stockholders’ equity:Additional paid-in capital79,982,98177,234,374
Stockholders’ equity:Accumulated deficit-74,574,859-67,520,328
Stockholders’ equity:Accumulated other comprehensive loss-237,578-249,291
Stockholders’ equity:Total stockholders’ equity3,283,9857,562,582
Stockholders’ equity:Total liabilities and stockholders’ equity19,561,48520,871,108
Full release

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking... (truncated)n management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact

Information

Investor

Relations ir@ainos.com

Ainos,

Inc.

Condensed

Consolidated Balance Sheets

Ainos, Inc.

Condensed Consolidated

Statements of Operations

(Unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.